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Abstract: Tinnitus is a symptom frequently encountered by ear, nose, and throat practitioners. 
A causal treatment is rarely possible, and drug and nondrug treatment options are limited. 
One of the frequently prescribed treatments is Ginkgo biloba extract. Therefore, randomized, 
placebo-controlled clinical trials of Ginkgo biloba extract preparations were searched for and 
reviewed systematically. There is evidence of efficacy for the standardized extract, EGb 761® 
(Dr Willmar Schwabe GmbH & Co KG Pharmaceuticals, Karlsruhe, Germany), in the treatment 
of tinnitus from three trials in patients in whom tinnitus was the primary complaint. Supportive 
evidence comes from a further five trials in patients with age-associated cognitive impairment 
or dementia in whom tinnitus was present as a concomitant symptom. As yet, the efficacy of 
other ginkgo preparations has not been proven, which does not necessarily indicate ineffective-
ness, but may be due to flawed clinical trials. In conclusion, EGb 761®, a standardized Ginkgo 
biloba extract, is an evidence-based treatment option in tinnitus.
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Introduction
In an ear, nose, and throat office, one is confronted every day with patients suffering 
from tinnitus. The prevalence of tinnitus in adults is between 10% and 15%.1   According 
to the 1999–2004 National Health and Nutrition Examination Surveys, 50 million 
people in the US suffer from this condition.1 A British study involving 48,313 sub-
jects reported a 10.1% prevalence of tinnitus in the adult population,2 which increases 
with age.3 Tinnitus has been found to affect more men than women.4 Approximately 
25% of patients with tinnitus report an increase in severity over time.5 The 2010 
Australian Blue Mountains Hearing Study with over 2000 individuals observed over 
5 years that nearly one in five older adults suffered from tinnitus.6
Classification and characteristics
The patients showing up in the ear, nose, and throat office suffer from various degrees 
of tinnitus. Subjective tinnitus is the perception of sound in the absence of external 
acoustic stimulation. In contrast, objective tinnitus is where an external source, such as 
blood streaming phenomena or muscular cramps inside the middle ear, can be   identified. 
Subjective tinnitus is detectable only by the patient and can often be described as 
  crackling, ringing, or whistling. It can be continuous or intermittent, and the onset may 
be acute with or without hearing loss.4 Full or partial spontaneous remission is possible, 
but tinnitus often becomes a chronic condition.7 Tinnitus may have a considerable 
impact on mood, and cause depression, anger, and anxiety, which in turn may enhance Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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attention to tinnitus.8 The hearing sensation can be very 
annoying, so that the patient suffers from a compromised 
ability to concentrate and relax. This situation is considered a 
decompensated, pathological chronic tinnitus. A compensated 
chronic tinnitus is described as a hearing sensation without 
any disturbing quality.9
etiology
Jastreboff and Hazell suggest a neurophysiological model for 
tinnitus,10 ie, an abnormal processing of signals generated in 
the auditory nervous system, beginning at the sensory level 
of the cochlear hair cell to cochlear fibers and the nucleus in 
higher brain structures. In this model, tinnitus could be gen-
erated at different levels in the auditory processing system. 
  Hyperactivity or damage to the cochlear hair cells resulting 
in senseless signals would be translated by the brain into a 
kind of phantom hearing sensation associated with hearing 
loss. Depending on the site of damage, the tinnitus is called 
peripheral, in contrast with central tinnitus originating from 
higher central nervous damage. Many environmental, iatro-
genic, and genetic factors have been described as a potential 
cause of hearing impairment and tinnitus, the most relevant 
being acoustic trauma, chronic exposure to occupational or 
work-related noise, and drug-related impairment caused by 
loop diuretics, antibiotics, chemotherapeutics, and salicy-
lates.4 An overview of possible causes is provided in Table 1. 
However, in 10%–20% of patients no cause for tinnitus can 
be found, and this is commonly referred to as “idiopathic 
tinnitus”.11
The pathological changes at the level of the inner ear 
hair cells include damage to the mitochondrial DNA or 
  endothelial damage with dysfunction of microcirculation.12,13 
The   underlying mechanism of ototoxicity varies with 
different drugs. According to Schacht, for example, 
  aminoglycoside antibiotics can cause loss of cochlear outer 
hair cells secondary to damage from free radicals and accu-
mulation of calcium and potassium ions.14,15
Treatment
Tinnitus is complex and multifactorial, and involves many 
etiological loci.3 Until now, there has been no specific 
therapy for all the different kinds of tinnitus. Current 
schemes include the use of hearing aids, counseling, sup-
portive therapy including tinnitus retraining therapy, and 
different medications such as vasodilators, corticosteroids, 
anticonvulsants, spasmolytic drugs, lidocaine, benzodiaz-
epines, and Gingko biloba preparations.4
EGb 761® (Dr Willmar Schwabe GmbH & Co KG 
Pharmaceuticals, Karlsruhe, Germany) is a dry extract from 
Ginkgo biloba leaves (35-67:1), extraction solvent: acetone 
60% (w/w). The extract is adjusted to 22.0–27.0% ginkgo 
flavonoids calculated as ginkgo flavone glycosides and 
5.0–7.0% terpene lactones consisting of 2.8–3.4% ginkgolides 
A, B, C and 2.6–3.2% bilobalide and contains less than 5 ppm 
ginkgolic acids. It is known to enhance microperfusion by 
increasing red blood cell deformability and decreasing whole 
blood viscosity.16,17 In a cat model, it specifically increased 
the blood flow in the cochlea.18   Moreover, EGb 761® protects 
Table 1 Causes of tinnitus (according to Lockwood)4
TYPE CAUSES
Subjective tinnitus
  Otologic Noise-induced  hearing  loss,  presbycusis,  otosclerosis,  otitis,  impacted  cerumen,  sudden 
deafness, Ménière’s disease, and other causes of hearing loss
  Neurologic Head  injury,  whiplash,  multiple  sclerosis,  vestibular  schwannoma  (commonly  called  an 
acoustic neuroma) or other cerebellar-pontine-angle tumors
  infectious Otitis media and sequelae of Lyme disease, meningitis, syphilis, and other infectious or 
inflammatory processes that affect hearing
  Drug-related Common  side  effect  of  many  drugs,  such  as  salicylates,  nonsteroidal  antiinflammatory 
drugs, aminoglycoside antibiotics, loop diuretics, and chemotherapy agents (eg. platins and 
vincristine)
  Other Temporomandibular-joint dysfunction and other dental disorders
Objective Tinnitus
  Pulsatile Carotid stenosis, arteriovenous malformations, other vascular anomalies, vascular tumors 
(eg.,  of  the  glomus  jugulare),  valvular  heart  disease  (usually  aortic  stenosis),  states  of 
high cardiac output (anemia and drug-induced high output), and other conditions causing 
turbulent blood flow
  Muscular or anatomical Palatal myoclonus, spasm of stapedius or tensor tympani muscle, patulous eustachian tube
  Spontaneous Spontaneous otoacoustic emissions
Note: Reproduced with permission from Lockwood AH, Salvi RJ, Burkard RF. Tinnitus. N Engl J Med. 2002;347(12):904–910. © 2002 The New England Journal of Medicine.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the mitochondria from oxidative stress and improves energy 
metabolism,19,20 thus attenuating damage to cochlear cells 
subject to increased energy demand or decreased perfusion. 
In a rat model of salicylate-induced tinnitus, Jastreboff et al 
demonstrated that EGb 761® treatment resulted in a signifi-
cant decrease in the behavioral manifestations of tinnitus.21 
Cisplatin-induced hair cell loss in rats, as well as subsequent 
alterations of endocochlear potentials and auditory brain stem 
responses, could be   prevented by EGb 761®.22
Randomized controlled trials of a variety of Ginkgo biloba 
extracts in the treatment of tinnitus have shown   different 
results, and reviews published during recent years have arrived 
at different conclusions. The objective of this review was to 
assess the methodological quality of available randomized 
controlled trials of Ginkgo biloba extract in   tinnitus, and to 
provide a synopsis of the evidence of efficacy for each specific 
extract. The results will be discussed in the context of former 
reviews, the scientific soundness of which will be evaluated.
Methods
Randomized, placebo-controlled, double-blind trials that met the 
following criteria were eligible for inclusion in this review:
•	 Use of an identifiable, standardized Ginkgo biloba extract, 
the composition of which is described adequately
•	 Dosing and duration of treatment appropriate for type 
of tinnitus
•	 Enrollment of inpatients or outpatients suffering from 
tinnitus as the primary or concomitant complaint
•	 No major methodological shortcomings or bias
•	 Publication in English, French, German, Spanish, or 
  Italian language.
Trials of interest were identified by searching the PubMed 
database (from the beginning up to October 2010) using the 
search terms “Ginkgo” and “tinnitus”, by hand searching ref-
erences listed in such identified reviews and trial reports, and 
by requesting information on randomized controlled trials of 
any Ginkgo product on tinnitus from a manufacturer.
Characteristics of included and excluded studies are 
described in tabular format and reasons for exclusion of 
studies are provided. An overview of details and results of 
included studies is depicted in tabular format and summarized 
in a descriptive manner.
Results
The PubMed search yielded 57 hits, of which 46 could be 
ruled out as irrelevant by title and abstract. The search identi-
fied seven review articles dealing to a substantial degree with 
Ginkgo and tinnitus and four randomized controlled trials of 
Ginkgo extract and tinnitus. Another randomized, placebo-
controlled trial of the special extract, EGb 761®, in tinnitus 
was identified from the references given in one of the review 
articles and five randomized, placebo-controlled trials of 
EGb 761® in dementia or age-related cognitive impairment 
(including one for which publication was pending) were 
identified by the manufacturer contacted.
Three studies of patients with tinnitus as a primary com-
plaint fulfilled the inclusion criteria and were included in the 
review. Five studies on patients suffering from dementia or 
age-associated cognitive decline with tinnitus as a concomi-
tant complaint met the inclusion criteria and were included 
in the review. Details are provided in Table 2. The standard-
ized extract, EGb 761®, was used in all studies that fulfilled 
Table 2 Characteristics of included trials
Reference Patients Diagnoses
Tinnitus as primary complaint
  Morgenstern and Biermann23 57 patients, median age approximately  
46 years, 57% male
Chronic tinnitus, mean duration approximately  
3 years
  Morgenstern and Biermann24 99 patients, mean age 45.5 years Chronic tinnitus, mean duration 4.5 years
  Meyer25 100 patients, mean age 50.4 years, 52% male Acute or subchronic tinnitus, mean duration 134 days
Tinnitus as concomitant complaint in dementia or aging-related cognitive impairment
  ihl et al26 404 patients, mean age 65 years, 33% male Mild to moderate dementia (Alzheimer’s  
disease, vascular dementia or mixed form)  
associated with neuropsychiatric symptoms
  Napryeyenko et al27 395 patients, mean age 64 years, 28% male Mild to moderate dementia (Alzheimer’s  
disease, vascular dementia or mixed form)  
associated with neuropsychiatric symptoms
  Schneider et al* 72 patients, mean age 78 years, 47% male Tinnitus associated with Alzheimer’s disease
  Halama et al28 40 patients, mean age 66 years Mild to moderate cerebrovascular insufficiency
  eckmann and Schlag29 32 patients, aged 45–74 years, 60% male Tinnitus associated with cerebro  vascular insufficiency
Note: *Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. Ginkgo biloba (eGb 761®) effects on mood and neurosensory symptoms (dizziness, tinnitus) 
in elderly, demented patients: secondary results of a randomized, placebo-controlled, double-blind trial [unpublished data]. Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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all quality criteria set to determine eligibility for this review. 
Three randomized controlled trials were excluded from the 
review due to major shortcomings in study conduct and/or 
reporting.
In the open-label part of the trial reported by   Holgers 
et al,30 80 patients with chronic tinnitus were treated with 
29.2 mg per day of a Ginkgo product for two weeks. 
  Treatment responders (20 patients) were then treated for 
two weeks each with 29.2 mg per day of the Ginkgo product 
and placebo in randomized order. The Ginkgo product was 
identifiable, but not described adequately. The daily dose 
of 29.2 mg seems rather low compared with the daily doses 
of 120–240 mg of the standardized extract EGb 761®. A 
treatment period of 2 weeks is too short for chronic tin-
nitus, which is associated with cortical reorganization. 
Hence, patients reporting subjective improvement after 2 
week’s treatment were most likely to be those experiencing 
the largest placebo effect. Selection of such patients for the 
placebo-controlled part of the trial does not seem appropriate 
from a methodological point of view. A crossover design is 
not state of the art for proof of efficacy because of the pos-
sibility of carryover effects.
In a randomized, double-blind, placebo-controlled trial 
reported by Drew and Davies,31 1243 patients with chronic 
tinnitus were enrolled and treated with LI 1370 150 mg 
per day or placebo for 12 weeks. This study did not meet 
minimal standards of Good Clinical Practice. No personal 
contact between physicians and patients was required; 
as a consequence, the actual existence and identity of the 
patients could not be verified, nor was any medical or 
audiological examination performed. Of 1426 patients who 
were not excluded from the study, 183 were not selected and 
122 were withdrawn without reasons being given. Although 
patients were paired and then allocated treatment codes, 155 
patients who received study medication were unpaired at 
the end of the study, and only 363 pairs (726 patients) were 
accounted for in the primary analysis.
Rejali et al32 reported a randomized, placebo-controlled, 
double-blind trial involving 66 outpatients with tinnitus who 
were treated with 120 mg per day of a Ginkgo preparation or 
placebo for 12 weeks. Neither the type of Ginkgo prepara-
tion used is described nor is any information provided about 
composition or standardization. After 12 weeks’ treatment, 
51% of patients treated with placebo and 21% of those 
treated with Ginkgo were unable to attend the final visit. 
Concomitant illness was the reason for this in 27% and 12% 
of placebo-treated and Ginkgo-treated patients, respectively. 
There is reason to assume that concomitant illness, which 
was severe enough to prevent patients from clinic visits, 
interfered with the subjective self-assessment of tinnitus 
handicap and health status.
All eight randomized, placebo-controlled trials of the 
standardized Ginkgo biloba extract EGb 761® showed 
  statistically significant superiority of the active treatment 
over placebo. This holds for change in tinnitus volume/inten-
sity (assessed and significant in three studies) as well as for 
overall severity (assessed in six, significant in five studies). 
Hence, there is evidence of efficacy for this specific prepara-
tion in patients with tinnitus as a single or major complaint, 
as well as in subjects suffering from tinnitus associated with 
dementia or aging-related cognitive impairment. Details of 
individual studies and outcomes are provided in Table 3.
Discussion
In all identified and retrieved studies using the standardized 
Ginkgo biloba extract, EGb 761®, this specific preparation was 
found to be superior to placebo in the treatment of   tinnitus. 
None of the identified studies using other Ginkgo products 
found a difference from placebo. However, considering the 
methodological flaws of these studies, it would be imprudent 
to conclude that all these products are ineffective.
Several reviews addressing the efficacy of Ginkgo biloba 
have been published in recent years. Smith et al uncriti-
cally lumped together studies of different Ginkgo biloba 
preparations irrespective of their quality and   dosage.33 
They did not address the serious problems of the study by 
Drew and Davies,31 and concluded that there is no proven 
support for the efficacy of Ginkgo biloba treatment. They 
may have relied on publication in a peer-reviewed journal 
as proof of quality rather than going into the detection of 
flaws in the different publications. In a meta-analysis of 
trials of Ginkgo biloba in the treatment of tinnitus, Rejali 
et al also pooled studies using various Ginkgo products of 
different and partly unknown quality.32 Their conclusion was 
that Ginkgo biloba does not benefit patients with   tinnitus. 
Similarly, Hilton and Stewart included three   clinical trials 
with three different products in their Cochrane Review.34 
Although they contend that they applied rigorous meth-
odological criteria for study selection, they accepted two 
seriously flawed trials. They concluded that there was no 
statistical proof of an effective tinnitus treatment with 
Gingko. On the contrary, Holstein, who only included 
studies with Gingko biloba extract EGb 761® in his review, 
found evidence of efficacy for this standardized extract Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Results of included trials
Reference Treatment (orally  
unless stated otherwise)
Type of analysis, results (means ± SD or 95% CI  
unless stated otherwise)
Morgenstern  
and Biermann23
Part i: 
eGb 761®: 
57 patients, 
200 mg/d iv 
10 days 
Part ii: 
eGb 761®: 
30 patients, 
160 mg/day; 
placebo: 
27 patients; 
12 weeks
iTT-LOCF 
Part i: Tinnitus volume decreased by approximately 8 dB on average 
Part ii: (changes after end of part i) 
Change in tinnitus volume week 12: EGb 761® -3.5 ± 17.8 dB,  
Plc -1.9 ± 17.3 dB, P , 0.05 
Change in tinnitus volume week 8: EGb 761® -3.0 ± 17.6 dB,  
Plc -1.3 ± 16.2 dB, P , 0.05 
Change in tinnitus volume week 4: EGb 761® -5.8 ± 13.0 dB,  
Plc 0.0 ± 17.7 dB, P , 0.05 
Hearing loss at 3.0 kHz: eGb 761® -0.5 ± 7.1 dB,  
Plc +3.7 ± 7.7 dB, P , 0.05 
Hearing loss at 4.0 kHz: eGb 761® -4.8 ± 11.4 dB,  
Plc +4.3 ± 9.8 dB, P , 0.01 
Hearing loss at 6.0 kHz: eGb 761® -1.8 ± 13.8 dB,  
Plc +1.7 ± 6.4 dB, ns 
Hearing loss at 8.0 kHz: eGb 761® -2.2 ± 12.0 dB,  
Plc +1.7 ± 3.9 dB, ns 
(negative change in hearing loss means improvement) 
Rates of patients with self-assessed intensity of permanent tinnitus as annoying  
or very annoying: eGb 761® 59% at baseline, 37.9% at week 12; Plc 43.4% at baseline,  
47.8% at week 12
Morgenstern  
and Biermann24
eGb 761®: 
49 patients, 
120 mg/day; 
placebo: 
50 patients; 
12 weeks
iTT-LOCF 
Change in tinnitus volume in the more severely affected ear (baseline/week 12):  
  EGb 761® from 42.2 (36.6, 48.1) to 39.0 (31.9, 46.1), 
  Plc from 44.3 (39.2, 49.4) to 45.1 (39.1, 51.2), 
  P = 0.015 
Patients’ global impression of change: eGb 761® 31% improved, Plc 14% improved 
No significant differences between treatment groups regarding tinnitus volume in the less   
severely affected ear, subjective rating of tinnitus intensity and hearing loss.
Meyer25 eGb 761®: 
55 patients, 
160 mg/day; 
placebo: 
45 patients 
3 months
Type of analysis not specified 
Global rating of change: eGb 761® 40% much improved,  
Plc 24% much improved, P = 0.05 
Duration until disappearance or significant improvement in 50% of patients:  
eGb 761® 70 days, Plc 119 days (medians), P = 0.03 
Change in tinnitus intensity (scale 0–3): eGb 761® -1.0, Plc -0.67, P = 0.03 
Change in nuisance (scale 0–3): eGb 761® -0.84, Plc -0.59, P = 0.08
ihl et al26 eGb 761®: 
202 patients, 
240 mg/day; 
placebo: 
202 patients; 
24 weeks
iTT-LOCF 
11-point box scale* for tinnitus: 
  eGb 761®: -0.5 (-0.6, -0.3), Plc: -0.1 (-0.2, 0.0), P , 0.001
Napryeyenko  
et al27
eGb 761®: 
198 patients, 
240 mg/day; 
placebo: 
197 patients; 
22 weeks
iTT-LOCF 
11-point box scale for tinnitus: 
  eGb 761®: -1.1 ± 1.6 
  Plc: -0.0 ± 0.9 
  P = 0.003
Schneider  
et al**
eGb 761® high dose:  
19 patients, 240 mg/day; 
eGb 761® low dose:  
29 patients, 120 mg/day; 
placebo: 
24 patients; 
26 weeks
iTT-LOCF 
11-point box scale for tinnitus: 
  eGb 761® high dose: -2.1 ± 2.1, P = 0.003 vs Plc 
  eGb 761® low dose: -1.1 ± 2.1, P = 0.09 vs Plc 
  Plc: -0.2 ± 1.7
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Table 3 (Continued)
Reference Treatment (orally  
unless stated otherwise)
Type of analysis, results (means ± SD or 95% CI  
unless stated otherwise)
Halama et al28 eGb 761®: 
20 patients, 
120 mg/day; 
placebo: 
20 patients; 
12 weeks
Type of analysis not specified 
Severity rating tinnitus (scale 0–3): eGb 761® from 1.05 ± 1.05 to 0.45 ± 0.83,  
Plc from 1.25 ± 0.91 to 1.10 ± 0.97, P = 0.035
eckmann and  
Schlag29
eGb 761®: 
12 patients, 
120 mg/day; 
placebo: 
20 patients; 
30 days
Type of analysis not specified 
Tinnitus disappeared: eGb 761® 100%, Plc 50%, P , 0.005
Notes: *Consisting of 11 boxes numbered 0 to 10, with 0 representing no tinnitus and 10 representing extremely severe tinnitus. **Schneider LS, DeKosky ST, Farlow MR, 
Tariot PN, Hoerr R, Kieser M. Ginkgo biloba (eGb 761®) effects on mood and neurosensory symptoms (dizziness, tinnitus) in elderly, demented patients: secondary results 
of a randomized, placebo-controlled, double-blind trial [unpublished data]. Bold print = primary outcome measure, if defined. 
Abbreviations: CI, confidence interval; SD, standard deviation; IV, intravenous; ITT-LOCF, intention-to-treat, last value carried forward; Plc, placebo; ns, not significant.
from randomized, placebo-controlled trials, supported by 
findings from reference-controlled and uncontrolled trials 
in a more true-to-life setting.35
The efficacy of a plant extract depends on its composi-
tion, which is determined by the extraction process, the bio-
availability of its active compounds, which depends on the 
composition and the galenical formulation, and its   dosage. 
Products made from the same plant species by different 
production processes cannot be assumed to be bioequiva-
lent. Therefore, it is not possible to generalize findings from 
studies of one specific extract to other   products. Hence, 
lumping together studies of different Ginkgo products and 
trying to draw an overall conclusion about the efficacy of 
all of these products is not reasonable and is also contradic-
tory to the principles of evidence-based medicine (“… the 
conscientious, explicit, and judicious use of current best 
evidence in making decisions about the care of individual 
patients”).36 The question is not whether any treatment may 
benefit the individual patient but which treatment is most 
appropriate.
There are studies of various Gingko preparations which 
have shown no effect but these were of poor methodological 
quality. However, the currently available literature shows 
that there is evidence for the successful treatment of tinnitus 
with the Ginkgo biloba extract, EGb 761®. Of note, all trials 
using this extract consistently demonstrate its superiority 
over placebo. The average treatment effects may be limited 
in magnitude and not all patients seem to respond to the drug, 
yet, given the annoying and often disabling nature of tinnitus, 
even moderate improvements may have a considerable impact 
on patient quality of life. It is the ear, nose, and throat special-
ist’s responsibility to offer patients counseling, supportive 
care, and the best alternatives in treatments available for each 
individual patient. Considering the limited data from meth-
odologically sound, well controlled trials of other therapeutic 
options, the robust and consistent data available for tinnitus 
treatment with EGb 761® should be appreciated.
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